Literature DB >> 21179526

Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Krista L Lanctôt1, Ryan D Rajaram, Nathan Herrmann.   

Abstract

Available symptomatic therapies for the treatment of Alzheimer's disease (AD) have been based on known neurotransmitter dysfunctions associated with the illness. The second-generation cholinesterase inhibitors and the N-methyl D-aspartate receptor antagonist memantine have been widely prescribed and studied. Meta-analyses of these therapies were reviewed, focusing on effectiveness and tolerability. Although many of the meta-analyses demonstrate statistically significant improvements, some question if these benefits are sufficient to justify their current widespread and protracted use. This has spurred the development of new disease-modifying therapies that aim to have a greater impact on this debilitating illness.

Entities:  

Keywords:  Alzheimer's disease; beta amyloid; cholinesterase inhibitors; donepezil; galantamine; memantine; meta-analysis; rivastigmine; tacrine; tau protein

Year:  2009        PMID: 21179526      PMCID: PMC3002627          DOI: 10.1177/1756285609102724

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  115 in total

1.  Reduced risk of incident AD with elective statin use in a clinical trial cohort.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Donald J Connor; Lisa M Sparks; Carolyn Liebsack
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

2.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

Authors:  Michael T Heneka; Magdalena Sastre; Lucia Dumitrescu-Ozimek; Anne Hanke; Ilse Dewachter; Cuno Kuiperi; Kerry O'Banion; Thomas Klockgether; Fred Van Leuven; Gary E Landreth
Journal:  Brain       Date:  2005-04-07       Impact factor: 13.501

3.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

5.  The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.

Authors:  K Hoglund; K M Thelen; S Syversen; M Sjogren; K von Bergmann; A Wallin; E Vanmechelen; H Vanderstichele; D Lutjohann; K Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2005-03-21       Impact factor: 2.959

Review 6.  Vascular risk factors and Alzheimer's disease.

Authors:  David F Cechetto; Vladimir Hachinski; Shawn N Whitehead
Journal:  Expert Rev Neurother       Date:  2008-05       Impact factor: 4.618

Review 7.  Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.

Authors:  Nathan Herrmann; Krista L Lanctôt
Journal:  Can J Psychiatry       Date:  2007-10       Impact factor: 4.356

8.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice.

Authors:  René Etcheberrigaray; Mathew Tan; Ilse Dewachter; Cuno Kuipéri; Ingrid Van der Auwera; Stefaan Wera; Lixin Qiao; Barry Bank; Thomas J Nelson; Alan P Kozikowski; Fred Van Leuven; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

9.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

10.  Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study.

Authors:  Weili Xu; Chengxuan Qiu; Margaret Gatz; Nancy L Pedersen; Boo Johansson; Laura Fratiglioni
Journal:  Diabetes       Date:  2008-10-24       Impact factor: 9.461

View more
  24 in total

Review 1.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

Review 2.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID).

Authors:  Nathan Herrmann; Tetsuhiro Harimoto; Robert Balshaw; Krista L Lanctôt
Journal:  Can J Psychiatry       Date:  2015-04       Impact factor: 4.356

Review 4.  The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.

Authors:  William James Deardorff; Eliahu Feen; George T Grossberg
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

5.  Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.

Authors:  Mario Riverol; Andrea Slachevsky; Oscar L López
Journal:  Eur Neurol J       Date:  2011-07-01

6.  Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators.

Authors:  Jun Qin; Wei Zhou; Xianhai Huang; Pawan Dhondi; Anandan Palani; Robert Aslanian; Zhaoning Zhu; William Greenlee; Mary Cohen-Williams; Nicholas Jones; Lynn Hyde; Lili Zhang
Journal:  ACS Med Chem Lett       Date:  2011-03-29       Impact factor: 4.345

7.  Bilateral deep brain stimulation of the fornix for Alzheimer's disease: surgical safety in the ADvance trial.

Authors:  Francisco A Ponce; Wael F Asaad; Kelly D Foote; William S Anderson; G Rees Cosgrove; Gordon H Baltuch; Kara Beasley; Donald E Reymers; Esther S Oh; Steven D Targum; Gwenn S Smith; Constantine G Lyketsos; Andres M Lozano
Journal:  J Neurosurg       Date:  2015-12-18       Impact factor: 5.115

8.  mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent.

Authors:  Khaled S Abd-Elrahman; Alison Hamilton; Awatif Albaker; Stephen S G Ferguson
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-12

Review 9.  Olive Oil Polyphenols in Neurodegenerative Pathologies.

Authors:  Constantinos Salis; Louis Papageorgiou; Eleni Papakonstantinou; Marianna Hagidimitriou; Dimitrios Vlachakis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Cardiorenal metabolic syndrome and diabetic cognopathy.

Authors:  M R Hayden; W A Banks; G N Shah; Z Gu; J R Sowers
Journal:  Cardiorenal Med       Date:  2013-11-29       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.